Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 604 trials

Atopic Dermatitis: PF-07275315 and PF-07264660

We are investigating two new treatments for adults with moderate to severe atopic dermatitis. The study aims to see if they are more effective than a placebo in reducing eczema symptoms.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsCost ReimbursementPartially RemoteAllergologyDermatology

Blood Pressure Response: Multi-Omics Study

We are exploring how specific biomarkers can predict the effectiveness of blood pressure medications for individuals. This study aims to improve treatment personalization and understand potential side effects.

Essential Hypertension3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Treatment-Resistant Depression: COMP360 Study

We are studying whether two doses of COMP360 can improve symptoms in adults with treatment-resistant depression. This trial includes psychological support to enhance treatment effects.

Major Depressive DisorderTreatment-Resistant Depression6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Coronary Disease: Tirzepatide Study

We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.

Overweight and Obesity1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Diffuse Large B-Cell Lymphoma: Epcoritamab with R-CHOP

We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.

Diffuse Large B-Cell Lymphoma1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

Hepatocellular Adenoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

Multiple Sclerosis Relapse1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsNeurology

Triple Negative Breast Cancer: Capecitabine and Pembrolizumab Study

We are studying the effects of capecitabine combined with pembrolizumab in patients with triple negative breast cancer after surgery and chemotherapy. This trial aims to see if this combination improves survival rates compared to standard treatments.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

DLBCL Treatment: Dexrazoxane for Heart Protection

We are studying whether dexrazoxane can help prevent heart problems in patients with diffuse large B-cell lymphoma receiving chemotherapy. This trial will also compare treatment responses and monitor any side effects.

Diffuse Large B-Cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyOncology

Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are analyzing how well sacituzumab govitecan works for patients with advanced breast cancer. The study will also assess safety and explore biomarkers that may predict treatment response.

Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Stomach Cancer: MK-2870 Treatment Study

We are comparing a new treatment called MK-2870 to standard care for people with advanced stomach cancer. The goal is to see if MK-2870 can improve survival and manage symptoms better.

Adenocarcinoma of the Gastroesophageal Junction>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Head and Neck Cancer: Ficlatuzumab and Cetuximab Study

We are investigating whether the combination of ficlatuzumab and cetuximab improves survival in adults with recurrent or metastatic HPV-negative head and neck cancer. This study compares the effects of this combination to a placebo treatment.

Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Posaconazole for Young Children with Fungal Infections

We are studying how well Posaconazole works and its safety in children under 2 years old with invasive fungal infections. This research will help us understand its effects compared to older patients.

Fungal Infection3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPediatrics

Chronic Kidney Disease: Patiromer Study

We are testing whether patiromer helps patients with chronic kidney disease better manage their blood pressure and reduce protein in urine. This study aims to improve treatment options for those with advanced kidney disease.

Chronic Kidney Disease6-12 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyNephrology

Non-Small-Cell Lung Cancer: Amivantamab Treatment Study

We are studying the effects of a new antibody treatment, amivantamab, alone and with chemotherapy for patients with early-stage lung cancer. This research aims to see if it helps before surgery and how it affects tumor characteristics.

Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Hypophosphatasia: ALXN1850 Treatment Study

We are studying a new treatment called ALXN1850 for adolescents and adults with hypophosphatasia who haven't been treated before. The goal is to see if it improves their daily functioning and quality of life compared to a placebo.

Hypophosphatasia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyHematology

Graft-versus-Host Disease: MC0518 Treatment Study

We are testing a new treatment, MC0518, for adults and adolescents with steroid-refractory acute graft-versus-host disease after stem cell transplantation. The study aims to see if it works better than the best available therapy and how it affects patients' quality of life.

Steroid Refractory Acute Graft Versus Host DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Immune Thrombocytopenia: New Combination Therapy

We are studying a new treatment combining four medications for patients with immune thrombocytopenia. The trial will evaluate its effectiveness, safety, and impact on quality of life.

Immune ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Nonsegmental Vitiligo: Ritlecitinib Study

We are investigating the safety and effectiveness of ritlecitinib in adults and adolescents with nonsegmental vitiligo. This study looks at how well the medication works over time for those who have already been treated.

Non-Segmental Vitiligo1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology